Adjunct therapy for recurrent and metastatic  endometrial carcinoma or renal  carcinoma


Ethinyl oestrdiol, norethindione, norgestrel, desogestrel, levonorgesrtrel, medoxyprogesterone, progesterone

Anaphylactic and anaphylactoid reactions, thrombophlebitis (in high doses).
Fatigue, insomnia, dizziness, headache, urticaria, atopecia, nausea, breast tenderness,
 galactorrhoea, decrease in glucose tolerance.
 I/M-pain at site of injection and gluteal abscess.

 

Hypersens,undiagnosed uterine bleeding,hematuria,pregnancy.

Special precautions:
Severe liver dysfunction, phebitis, hypertension, diabetes.

 

Indications:
Adjunct therapy for recurrent and metastatic  endometrial carcinoma or renal  carcinoma


Dosage:
For  IM administration only
Endometrial or renal carcinoma - 400 to 1000mg/week.  May be possible to maintain
improvement with as little as  400mg/mth.



 

Contraindicated for use during pregnancy
Observe caution